Gene Therapy Developers Rise on Comments From FDA's Makary
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 29% Dive
REGENXBIO Is Maintained at Neutral by Goldman Sachs
Goldman Sachs Maintains Regenxbio(RGNX.US) With Hold Rating, Cuts Target Price to $12
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $25
RBC Cuts Price Target on REGENXBIO to $25 From $30, Keeps Outperform, Speculative Risk
Clear Street Initiates Regenxbio(RGNX.US) With Buy Rating, Announces Target Price $50
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $34
Optimistic Buy Rating for RegenXBio Driven by Promising RGX-202 Developments in DMD Treatment
Analysts Are Neutral on These Healthcare Stocks: Medtronic (MDT), RegenXBio (RGNX)
Regenxbio's DMD Gene Therapy Drives 122.3% Biomarker Uptick in Three-year-old
REGENXBIO Price Target Maintained With a $52.00/Share by Chardan Capital
REGENXBIO Is Maintained at Buy by Chardan Capital
Regenxbio Analyst Ratings
Baird Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $39
Raymond James Maintains Regenxbio(RGNX.US) With Buy Rating, Raises Target Price to $29
Sector Update: Health Care Stocks Lower in Afternoon Trading
Express News | Regenxbio Shares up 5.6% on Early Data From Gene Therapy for Muscle Disorder